121 Bibliografia [1] Complicazioni a lungo termine ed effetti collaterali dopo trapianto allogenico di cellule staminali ematopoietiche: un aggiornamento - diario del cancro del sangue, Consultato il 24 agosto 2022. https://ita.legatechnics.com/long-term-complications-32936613 [2] Caristo, T. «Indicazioni per il follow-up a lungo termine del paziente post-trapianto allogenico». Consultato 24 agosto 2022. http://www.reteoncologica.it/area-operatori/gruppi-su-temi-oncologici/tossicita-tardive-delle-terapie-oncologiche/588-raccomandazioni-2/2846-indicazioni-per-il-follow-up-a-lungo-termine-del-paziente-post-trapianto-allogenico. [3] Kutney-Lee A, Lake ET, Aiken LH. Development of the Hospital Nurse Surveillance Capacity Profile. Res Nurs Health. 2009 Apr;32(2):217-28. doi: 10.1002/nur.20316. PMID: 19161172; PMCID: PMC2906760. [4] Kenyon M, Babic A, editors. The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT [Internet]. Cham (CH): Springer; 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK543668/ doi: 10.1007/9783-319-50026-3 [5] Chronic GVHD Activity Assessment-Patient Self-Reported, consultato il 24/8/2022 https://www.researchgate.net/figure/ Chronic-GVHD-Activity-Assessment-Patient-Self-Report_ fig2_273889223 [6] McQuellon, R., Russell, G., Rambo, T. et al. Quality of life and psychological distress of bone marrow transplant recipients: the 1. Aspetti Generali ‘time trajectory’ to recovery over the first year. BoneMarrow Transplant 21, 477–486 (1998). https://doi.org/10.1038/sj.bmt.1701115). [7] Niederbacher S, Them C, Pinna A, Vittadello F, Mantovan F. Patients’ quality of life after allogeneic haematopoietic stem cell transplantation: mixed-methods study. Eur J Cancer Care. 2012;21(4):548–59. [8] Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, Juvonen E, Marshall S, Photopheresis Expert Group. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graftversus-host disease. Br J Dermatol. 2008; 158:659–78. [9] Lee SJ, Flowers MED. Recognizing and managing chronic graft-versus-host disease. In: Gewirtz AM, Muchmore EA, Burns LJ, editors. Haematology 2008: American Society of Haematology Education Program Book. Washington, DC: American Society of Haematology; 2008. p. 134–41 [10] Lee SJ, Vogelsang G, Flowers MED. Chronic graftversus-host disease. Biol Blood Marrow Transplant. 2003; 9:215–33 [11] Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng S, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers MED. National Institutes of Health chronic graft-versushost disease consensus for clinical trials: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401 [12] Carpenter P. How I conduct a comprehensive chronic graftversus-host disease assessment. Blood. 2011;118(10):2679–87
RkJQdWJsaXNoZXIy ODUzNzk5